Primary care physician knowledge, attitudes, and diagnostic testing practices for norovirus and acute gastroenteritis


Autoři: Cristina V. Cardemil aff001;  Sean T. O’Leary aff002;  Brenda L. Beaty aff002;  Katy Ivey aff001;  Megan C. Lindley aff001;  Allison Kempe aff002;  Lori A. Crane aff002;  Laura P. Hurley aff002;  Michaela Brtnikova aff002;  Aron J. Hall aff001
Působiště autorů: National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, United States aff001;  Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, United States aff002;  Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States aff003;  Department of Community and Behavioral Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States aff004;  Division of General Internal Medicine, Denver Health, Denver, CO, United States aff005
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227890

Souhrn

Background

Norovirus is a leading cause of acute gastroenteritis (AGE) across the age spectrum; candidate vaccines are in clinical trials. While norovirus diagnostic testing is increasingly available, stool testing may not be performed routinely, which can hamper surveillance and burden of disease estimates. Additionally, lack of knowledge of the burden of disease may inhibit provider vaccine recommendations, which could affect coverage rates and ultimately the impact of the vaccine. Our objectives were to understand physicians’ stool testing practices in outpatients with AGE, and physician knowledge of norovirus, in order to improve surveillance and prepare for vaccine introduction.

Methods

Internet and mail survey on AGE, norovirus, and future norovirus vaccines conducted January to March 2018 among national networks of primary care pediatricians, family practice and general internal medicine physicians.

Results

The response rate was 59% (820/1383). During peak AGE season, physicians estimated they ordered stool tests for a median of 15% (interquartile range: 5–33%) of their outpatients with AGE. Stool tests were reported as more often available for ova and parasites, Clostridioides difficile, and bacterial culture (>95% for all specialties) than for norovirus (6–33% across specialties); even when available, norovirus-specific tests were infrequently ordered. Most providers were unaware that norovirus is a leading cause of AGE across all age groups (Pediatricians 80%, Family Practice 86%, General Internal Medicine 89%) or that alcohol-based hand sanitizers are ineffective against norovirus (Pediatricians 51%, Family Practice 66%, General Internal Medicine 62%). Concerns cited as major barriers to implementing a future norovirus vaccine included if the vaccine is not covered by insurance (General Internal Medicine 64%, Pediatricians 67%, Family Practice 74%) and lack of adequate reimbursement for vaccination (Pediatricians 43%, General Internal Medicine 46%, Family Practice 50%). Factors that providers believed were ‘not at all a barrier’ or ‘minor barrier’ to new vaccine introduction included the belief that “my patients won’t need this vaccine” (General Internal Medicine 78%, Family Practice 86%, Pediatricians 90%) and “my patients already get too many vaccines” (Family Practice 89%, General Internal Medicine 92%, Pediatricians 95%).

Conclusions

Primary care physicians had few concerns regarding future norovirus vaccine introduction, but have knowledge gaps on norovirus prevalence and hand hygiene for prevention. Also, physicians infrequently order stool tests for outpatients with AGE, which limits surveillance estimates that rely on physician-ordered stool diagnostics. Closing physician knowledge gaps on norovirus burden and transmission can help support norovirus vaccine introduction.

Klíčová slova:

Diagnostic medicine – Disease surveillance – Norovirus – Outpatients – Pediatrics – Physicians – Public and occupational health – Vaccines


Zdroje

1. Hall AJ, Lopman BA, Payne DC, Patel M, Gastanaduy P, Vinje J, et al. Norovirus disease in the United States. Emerg Infect Dis 2013;19(8): 1198–205. doi: 10.3201/eid1908.130465 23876403

2. Shah MP, Hall AJ. Norovirus Illnesses in Children and Adolescents. Infect Dis Clin North Am. 2018 Mar;32(1):103–118. doi: 10.1016/j.idc.2017.11.004 29406972

3. Payne DC, Vinjé J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med. 2013 Mar 21;368(12):1121–30. doi: 10.1056/NEJMsa1206589 23514289

4. Cardemil CV, Parashar UD, Hall AJ. Norovirus Infection in Older Adults: Epidemiology, Risk Factors, and Opportunities for Prevention and Control. Infect Dis Clin North Am. 2017 Dec;31(4):839–870. doi: 10.1016/j.idc.2017.07.012 28911830

5. Mattison CP, Cardemil CV, Hall AJ. Progress on norovirus vaccine research: public health considerations and future directions. Expert Rev Vaccines. 2018 Sep;17(9):773–784. doi: 10.1080/14760584.2018.1510327 30092671

6. Mateo R, Lin K, Kolhatkar N, Taylor D, Garg S, Tucker S. 78. Oral Norovirus Vaccination in Humans Induces Plasmablast B-Cell Expansion and Follicular T-Cell Activation Comparable to Natural Infection. Open Forum Infect Dis. 2019 Oct; 6(Suppl 2): S2. Published online 2019 Oct 23. doi: 10.1093/ofid/ofz359.002 PMCID: PMC6808692.

7. Masuda T, Lefevre I, Mendelman P, Sherwood J, Bizjajeva S, Borkowski A. 2276. Immunogenicity of Takeda’s Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age. Open Forum Infect Dis. 2018 Nov; 5(Suppl 1): S674. Published online 2018 Nov 26. doi: 10.1093/ofid/ofy210.1929 PMCID: PMC6255068.

8. Yen C, Hall AJ. Editorial Commentary: Challenges to Estimating Norovirus Disease Burden. J Pediatric Infect Dis Soc. 2013 Mar;2(1):61–2. doi: 10.1093/jpids/pis134 26619443

9. Harris JP. Norovirus Surveillance: An Epidemiological Perspective. J Infect Dis. 2016 Feb 1;213 Suppl 1:S8–S11.

10. Vinje J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol 2015;53(2):373–81. doi: 10.1128/JCM.01535-14 24989606

11. Crane LA, Daley MF, Barrow J, Babbel C, Stokley S, Dickinson LM et al. Sentinel physician networks as a technique for rapid immunization policy surveys. Eval Health Prof 2008 Mar; 31(1):43–64. doi: 10.1177/0163278707311872 18184632

12. Dillman DA, Smyth J, Christian LM. Internet, Mail and Mixed-Mode Surveys: The Tailored Design Method. 3rd ed. New York, NY: John Wiley Co.; 2009.

13. McMahon SR, Iwamoto M, Massoudi MS, Yusuf HR, Stevenson JM, David F, et al. Comparison of e-mail, fax, and postal surveys of pediatricians. Pediatrics. 2003;111(4 Pt 1):e299–303.

14. Atkeson LR, Adams AN, Bryant LA, Zilberman L, Saunders KL. Considering Mixed Mode Surveys for Questions in Political Behavior: Using the Internet and Mail to Get Quality Data at Reasonable Costs. Political Behavior. 2011;33(1):161–178.

15. Hall AJ, Rosenthal M, Gregoricus N, Green SA, Ferguson J, Henao OL et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005, Emerg Infect Dis 2011: 17(8).

16. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol. Mar 21, 2016; 22(11): 3078–3104. doi: 10.3748/wjg.v22.i11.3078 27003987

17. Brennan-Krohn T. Multiplex Gastrointestina Pathogen Panels: The Promise and the Peril. Clinical Microbiology: Bugs and Drugs, 16 Feb 2018 18:20.

18. Zhang H, Morrison S, Tang Y. Multiplex PCR Tests for Detection of Pathogens Associated with Gastroenteritis. Clin Lab Med. 2015 Jun; 35(2):461–486. doi: 10.1016/j.cll.2015.02.006 26004652

19. Cardemil CV, Kambhampati A, Grytdal S, Rodriguez-Barradas MC, Vargas B, Beenhouwer DO, et al. Incidence of norovirus and rotavirus from multisite active surveillance in Veteran’s Affairs hospitals, December 2016–February 2018: results from the SUPERNOVA network. Oral presentation at IDWeek, October 5, 2018, San Francisco.

20. Schmidt MA, Groom HC, Naleway AL, Biggs C, Salas SB, Shioda K et al. A model for rapid, active surveillance for medically-attended acute gastroenteritis within an integrated health care delivery system. PLoS One. 2018 Aug 3;13(8):e0201805. doi: 10.1371/journal.pone.0201805 30075030

21. Guideline for Hand Hygiene in Health-Care Settings Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Morbidity and Mortality Weekly Report. October 25, 2002/Vol 51/No.RR-16.

22. Hall AJ, Vinje J, Lopman B, Park GW, Yen C, Gregoricus N, et al. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011;60(RR-03):1–18.

23. Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how infectious is it? J Med Virol 2008;80:1468–76. doi: 10.1002/jmv.21237 18551613

24. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis 2014;209(7):1016–22. doi: 10.1093/infdis/jit620 24253285

25. Shimizu-Onda Y, Akasaka T, Yagyu F, Komine-Aizawa S, Tohya Y, Hayakawa S, et al. The virucidal effect against murine norovirus and feline calicivirus as surrogates for human norovirus by ethanol-based sanitizers. J Infect Chemother. 2013 Aug;19(4):779–81. doi: 10.1007/s10156-012-0516-2 Epub 2012 Nov 8. 23135829

26. Macinga DR, Sattar SA, Jaykus LA, Arbogast JW. Improved inactivation of nonenveloped enteric viruses and their surrogates by a novel alcohol-based hand sanitizer. Appl Environ Microbiol. 2008 Aug;74(16):5047–52. doi: 10.1128/AEM.00487-08 Epub 2008 Jun 27. 18586970

27. Steinmann J, Becker B, Bischoff B, Steinmann E. Alcohol hand rub or soap and water for removal of norovirus from hands–the debate continues. Journal of Hospital infection, 91(4): 2015: 371–372. doi: 10.1016/j.jhin.2015.07.015 26518271

28. Park GW, Barclay L, Macinga D, Charbonneau D, Pettigrew CA, Vinjé J. Comparative efficacy of seven hand sanitizers against murine norovirus, feline calicivirus, and GII.4 norovirus. J Food Prot. 2010 Dec;73(12):2232–8. doi: 10.4315/0362-028x-73.12.2232 21219741

29. Tuladhar E., Hazeleger W.C., Koopmans M., Zwietering MH, Duizer E, Beumer RR. Reducing viral contamination from finger pads: handwashing is more effective than alcohol-based hand disinfectants J Hosp Infect, 90 (2015), pp. 226–234. doi: 10.1016/j.jhin.2015.02.019 25936671

30. Vogel L. Hand sanitizers may increase norovirus risk. Can Med Assoc J, 183 (2011), pp. E799–E800.

31. Costantini V, Morantz EK, Browne H, Ettayebi K, Zeng XL, Atmar RL et al. Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation. Emerg Infect Dis. 2018 Aug;24(8):1453–1464. doi: 10.3201/eid2408.180126 30014841

32. Liu P, Yuen Y, Hsiao HM, Jaykus LA, Moe C. Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands. Appl Environ Microbiol. 2010 Jan;76(2):394–9. doi: 10.1128/AEM.01729-09 Epub 2009 Nov 20. 19933337

33. Sandora TJ, Shih MC, Goldmann DA. Reducing absenteeism from gastrointestinal and respiratory illness in elementary school students: a randomized, controlled trial of an infection-control intervention. Pediatrics. 2008 Jun;121(6):e1555–62. doi: 10.1542/peds.2007-2597 18519460

34. Kirk J, Kendall A, Marx JF, Pincock T, Young E, Hughes JM et al. Point of care hand hygiene—where's the rub? A survey of US and Canadian health care workers' knowledge, attitudes, and practices. American Journal of Infection Control 2016; 44(10): 1095–1101. doi: 10.1016/j.ajic.2016.03.005 27178035

35. Hurley LP, Bridges CB, Harpaz R, Allison MA, O'Leary ST, Crane LA, et al. U.S. physicians’ perspective of adult vaccine delivery. Ann Intern Med. 2014;160(3):161. doi: 10.7326/M13-2332 24658693


Článek vyšel v časopise

PLOS One


2020 Číslo 1